Spliceosome-Targeted Therapies Induce dsRNA Responses

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Spliceosome-targeted therapies are emerging cancer treatments.
• Tumor cells often evade immune detection.
• Antiviral signaling pathways can be harnessed for cancer therapy.

Purpose of the Study:

• To elucidate the mechanism by which spliceosome-targeted therapies activate anti-tumor immunity.
• To investigate the role of intron-containing transcripts in immune activation.
• To explore the potential of viral mimicry as an immunotherapeutic strategy.

Main Methods:

• Analysis of intron-containing transcripts in cells treated with spliceosome inhibitors.
• Assessment of double-stranded RNA (dsRNA) formation.
• Evaluation of downstream antiviral signaling pathway activation (e.g., RIG-I, MDA5).
• Measurement of adaptive immune responses in pre-clinical models.

Main Results:

• Spliceosome inhibition leads to the accumulation of intron-containing transcripts.
• These transcripts form double-stranded RNAs (dsRNAs).
• The dsRNAs trigger viral mimicry, activating innate antiviral signaling.
• This activation enhances downstream adaptive anti-tumor immunity.

Conclusions:

• Spliceosome-targeted therapies can induce an anti-tumor immune response through dsRNA formation and viral mimicry.
• This mechanism represents a novel approach to cancer immunotherapy.
• Combining spliceosome inhibition with immunotherapies may enhance treatment efficacy.